Tag: CD19 CD20 immunotherapy FL

Home / CD19 CD20 immunotherapy FL

Categories

Tafasitamab-cxix is approved by the USFDA for relapsed or refractory follicular lymphoma

On June 18, 2025, the Food and Drug Administration sanctioned tafasitamab-cxix (Monjuvi, Incyte Corporation) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory folli...
cd19-cd20-immunotherapy-fl

Scan the code